MedTrace Logo

VOCs in Kidney and Liver Transplants

NCT04514666 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-04-20

No results posted yet for this study

Summary

Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease.

Chronic rejection may occur in 3 to 17% livers transplants and in 20 to 40% kidney transplants.

While acute rejection is clearly detected due to the clinical features and laboratory tools, the early identification of chronic rejection is still challenging since the clinical features are often silents and laboratory tests become suggestive when the damage due to the rejection is almost irreversible.

Considering the recent application of the breathomic to liver and kidney disease and the difficulty in the early detection of chronic rejection after liver and kidney transplants, the analysis of the exhaled VOCs pattern could help early detection of chronic rejection allowing a prompt medical treatment.

Conditions

  • Liver Transplant Rejection
  • Kidney Transplant; Complications

Interventions

OTHER

Breath analysis

The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified

Sponsors & Collaborators

  • Societa Italiana di Chirurgia ColoRettale

    lead NETWORK

Principal Investigators

  • Arcangelo Picciariello, MD · Societa Italiana di Chirurgia ColoRettale

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-02
Primary Completion
2022-10-02
Completion
2023-03-02

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04514666 on ClinicalTrials.gov